Recommendations for visual evaluations of patients treated with vigabatrin

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 442-446

  Sergott, Robert C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

infantile spasms; peripheral visual field defects; refractory epilepsy; vigabatrin; visual testing

Indexed keywords

VIGABATRIN;

ALGORITHM; CLINICAL PROTOCOL; DIAGNOSTIC TEST; HUMAN; INFANTILE SPASM; PATHOGENESIS; PERIMETRY; PRIORITY JOURNAL; RELIABILITY; REVIEW; STANDARDIZATION; VISION; VISUAL DISORDER; VISUAL FIELD; VISUAL IMPAIRMENT;

4-AMINOBUTYRATE TRANSAMINASE; ALGORITHMS; ANTICONVULSANTS; ENZYME INHIBITORS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RETINA; VIGABATRIN; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 78049274195     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833f0085     Document Type: Review

References (28)

1. Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36 (Suppl 2):S95-S104.
2. Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multi-centre study. The Canadian Vigabatrin Study Group. Seizure 2000; 9:224-232.
3. French JA, Mosier M, Walker S, et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996; 46:54-61.
4. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000; 9:112-118.
5. Sander JW, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 1990; 53:1008-1010.
6. Aicardi J, Mumford J, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996; 37:638-642.
7. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40:1627-1633.
8. Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990; 335:363-364.
9. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26:389-395.
10. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57:1416-1421.
11. Wohlrab G, Boltshauser E, Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998; 29:133-136.
12. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48:60-64.
13. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67:716-722.
14. Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40:1784-1794.
15. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50:614-618.
16. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53:2082-2087.
17. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116:817-819.
18. Durbin S, Mirabella G, Buncic JR, Westall CA. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest Ophthalmol Vis Sci 2009; 50:4011-4016.
19. Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary 'inverse' optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004; 111:1935-1942.
20. Harding GF, Wild JM, Robertson KA, et al. Electro-oculography, electrore-tinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000; 41:1420-1431.
21. Durnian JM, Clearkin LG. Retinal nerve fibre layer characteristics with viga-batrin-associated visual field loss: could scanning laser polarimetry aid diagnosis? Eye 2008; 22:559-563.
22. Lawthom C, Smith PE, Wild JM. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 2009; 116:565-571.
23. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181.
24. Frisen L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 2003; 81:466-473.
25. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106:1792-1798.
26. Choi HJ, Kim DM. Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation. J Neurol Neurosurg Psychiatry 2004; 75:1395.
27. Wild JM, Robson CR, Jones AL, et al. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006; 47:917-924.
28. Sergott RC, Wheless JW, Smith MC, et al. Evidence-based review of recommendations for visual function testing in patients treated with Vigabatrin. Neuro-Ophthalmology 2010; 34:20-35.